Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis

You may be eligible if

• patients with prostate cancer post radical radiation therapy and LHRH agonist treated in PCSIV clinical trial
• biochemical failure (PSA nadir + 2) or minimum follow-up of 3 years post completion of hormonal therapy
• high risk group
• 1. gleason score 8-10
• 2. PSA ≥ 20 ng/ml
• 3. T3 or T4